Biocogniv vs Pfizer

Side-by-side comparison of AI visibility scores, market position, and capabilities

Pfizer leads in AI visibility (93 vs 40)
Biocogniv logo

Biocogniv

EmergingHealthcare

General

FDA Breakthrough Device-designated AI platform predicting sepsis mortality risk in emergency departments; $17.08M from Breyer Capital and YC generating $2.6M revenue at 13-person Burlington-based team.

AI VisibilityBeta
Overall Score
C40
Category Rank
#359 of 596
AI Consensus
86%
Trend
stable
Per Platform
ChatGPT
42
Perplexity
41
Gemini
40

About

Biocogniv is a Burlington, Vermont-based clinical AI company that has developed an FDA Breakthrough Device Designation-granted platform for predicting sepsis-related mortality and ICU admission risk in emergency departments — using AI analysis of routine clinical data (vital signs, lab values, patient history) to identify patients at highest risk of deterioration hours before clinical signs become obvious to clinicians, enabling earlier intervention in one of healthcare's most time-sensitive conditions. Founded in 2019 and a Y Combinator W20 graduate, Biocogniv raised $17.08 million from Breyer Capital and YC, generating $2.6 million in revenue in 2024 with a 13-person team.

Full profile
Pfizer logo

Pfizer

LeaderHealthcare Tech

Enterprise

Global biopharma with $63.6B FY2024 revenue; $43B Seagen ADC acquisition rebuilds post-COVID pipeline; patent cliff 2026-2028 for Eliquis; activist Starboard Value pushing restructuring.

AI VisibilityBeta
Overall Score
A93
Category Rank
#1 of 596
AI Consensus
80%
Trend
stable
Per Platform
ChatGPT
94
Perplexity
89
Gemini
94

About

Pfizer is one of the world's largest biopharmaceutical companies, founded in 1849 by cousins Charles Pfizer and Charles Erhart in Brooklyn, New York, and now headquartered in New York City. The company trades on NYSE (PFE) and reported $63.6 billion in total revenues for FY2024, normalizing from pandemic highs of $100 billion-plus in 2021-2022 driven by Comirnaty COVID-19 vaccine revenues with BioNTech and Paxlovid COVID antiviral sales. CEO Albert Bourla has led a strategic pivot to reset the company's long-term growth profile, anchored by the landmark $43 billion acquisition of Seagen in December 2023, adding a world-class antibody-drug conjugate (ADC) oncology pipeline including Padcev, Tukysa, Adcetris, and Tivdak.

Full profile

AI Visibility Head-to-Head

40
Overall Score
93
#359
Category Rank
#1
86
AI Consensus
80
stable
Trend
stable
42
ChatGPT
94
41
Perplexity
89
40
Gemini
94
39
Claude
92
36
Grok
98

Key Details

Category
General
Enterprise
Tier
Emerging
Leader
Entity Type
brand
company

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.